Drug Profile
Amfetamine prodrug - Ensysce Biosciences
Alternative Names: Abuse-resistant amphetamine; Amfetamine - PharmacoFore; Amphetamine prodrug; Dexamfetamine - Ensysce Biosciences; Dexamphetamine - Ensysce Biosciences; PF-08; PF-8001; PF-8026; PF8001 / PF8026; PFR 08001; PFR08026Latest Information Update: 21 Oct 2022
Price :
$50
*
At a glance
- Originator PharmacoFore
- Developer Ensysce Biosciences
- Class Amphetamines; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Attention-deficit hyperactivity disorder
Most Recent Events
- 20 Oct 2022 Amfetamine prodrug (PF 8001/PF 8026) is still in preclinical trials for Attention-deficit hyperactivity disorder (ADHD) in US (Ensysce Biosciences pipeline, October 2022; https://ensysce.com/our-strategy/#preclinical-programs)
- 05 Aug 2021 Ensysce Biosciences receives Notice of Allowance for a patent entitled Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof in USA
- 28 Mar 2020 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in USA (PO, Controlled release)